Stocks fell and oil prices slid more than 3 per cent on Monday as surging Omicron COVID-19 cases triggered tighter curbs in Europe and US growth prospects dimmed after a $1.75 trillion domestic investment bill suffered a potentially fatal blow.
Under the support announced on Tuesday, hospitality and leisure firms in England will be eligible for grants of up to £6,000 for each of their premises, accounting for almost £700 million of the new package.
Britain’s economy grew more slowly than previously thought in the July-September period, before the Omicron variant of the coronavirus posed a further threat to the recovery later in the year, official data showed on Wednesday. Gross domestic product
Omicron infections have so far caused "mild" illness or asymptomatic cases, but the WHO said the data was insufficient to establish the variant's clinical severity.
British Prime Minister Boris Johnson said on Monday the first patient had died after contracting the Omicron variant of the coronavirus, Sky news reported.
Senior health official Vinod Kumar Paul told a news briefing that government experts were studying data on boosters but "our emphatic view...is to (first) cover every adult with (just) the primary two doses." The government has said this target can be achieved by January.
Hundreds of people queue outside St Thomas hospital in London to get their third dose of the COVID-19 vaccine, as the UK ramps up its rollout to ensure all adults can receive a booster by the end of December.
Scientists are still investigating the impact of the highly contagious Omicron variant, which was first detected in South Africa. Early evidence has suggested it may cause milder illness than its predecessors, including Delta.
India's capital New Delhi will lock down over the weekend as authorities grapple with a fresh surge in coronavirus cases, partly fuelled by the fast-spreading Omicron variant.
The teenagers, many wearing their uniforms, queued at schools and health centres across the country as health workers injected them with Bharat Biotech's Covaxin — the only COVID-19 vaccine so far approved by India for those below 18 years.